
#ENA2026 is underway in Barcelona, and our first poster is ready to explore! 👉 More about our presentations: lnkd.in/dUCzUJJd #FunduszeEuropejskie #FunduszeUE #ENA2026 #ADC #PrecisionOncology #ONCOPrime #PRMT5

Ryvu Therapeutics is developing novel small molecule therapies that address clinical limitations of current treatments in oncology.

#ENA2026 is underway in Barcelona, and our first poster is ready to explore! 👉 More about our presentations: lnkd.in/dUCzUJJd #FunduszeEuropejskie #FunduszeUE #ENA2026 #ADC #PrecisionOncology #ONCOPrime #PRMT5

MENARINI Group and Ryvu will present the first clinical data from the Phase II JASPIS-01 study of dapolsertib (MEN1703, SEL24) in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. Read more: lnkd.in/d5mf-Y3Z

The abstracts for the 2026 EORTC-NCI-AACR Symposium (#ENA) are now available online. Ryvu will present two posters featuring preclinical research: RVU602 and ONCO Prime Read more: lnkd.in/dRqJM39i Go to the abstracts: lnkd.in/eJYNE4cB



Ryvu presented new preclinical proof-of-concept data for RVU602, our proprietary, potentially first-in-class ADC payload with a mechanism of action distinct from both TOPO1 and tubulin inhibitors. 🔗 Read more: lnkd.in/dU5N4v6P



Aleksandra Sabiniarz, Director of Research Operations will represent Ryvu at the 25th Scientific Congress of the Polish Pharmaceutical Society in Wrocław, September 22-25. Ola will speak during the first plenary session. Learn more: ptfarmzjazd.pl/

Ryvu has signed a grant agreement with the National Centre for Research and Development. The agreement provides up to PLN 105.6 million in funding for the project “PANACEA-NOVO - patient-oriented innovative targeted therapies for rare cancers” lnkd.in/dr2v5YNj

Ryvu Therapeutics has reported its financial results for H1 2026 and provided an update on recent clinical and corporate progress. Read the H1 2026 report: lnkd.in/eh7jb6QU and the press release: lnkd.in/e4V8zD4H


Today, we are launching Keelira, our dedicated early clinical development services business for biotech and pharma companies seeking to extend oncology programs into Europe. Read the press release: ryvu.com/press-release/ryvu-… Learn more about Keelira: keelira.com

The MEDWAY project is moving forward, and we are proud to be part of it! The Children’s Memorial Health Institute officially launched a new investigator-initiated, non-commercial Phase I clinical study. More: ryvu.com/press-release/rvu12…

Thank you to Minister Pełczyńska-Nałęcz, Secretary of State Szyszko, and everyone from the Ministry of Development Funds and Regional Policy who joined us for an open and substantive conversation. We look forward to continuing this dialogue!
Po raz pierwszy w historii powstaje lek wynaleziony i w całości opracowany przez naszych naukowców i naszą rodzimą firmę. Tak warto budować rozwój. Wsparte z KPO i Funduszy 🇪🇺🇵🇱

Po raz pierwszy w historii powstaje lek wynaleziony i w całości opracowany przez naszych naukowców i naszą rodzimą firmę. Tak warto budować rozwój. Wsparte z KPO i Funduszy 🇪🇺🇵🇱